Document:

Exhibit 10.2

Exhibit 10.2

EXHIBIT 1(a)

This Note has not been registered pursuant to the Securities Act of 1933, as amended (the
“Securities Act"), or pursuant to the securities laws of any state. Accordingly, this Note may not
be offered, sold or otherwise transferred (1) except in accordance with an applicable exemption
from the registration requirements of the Securities Act and any applicable state securities laws
or (2) unless this Note is registered under the Securities Act and any applicable state securities
laws.

TRANSWESTERN PIPELINE COMPANY, LLC

5.36% Senior Unsecured Series A Note due December 9, 2020

	 	 	 
	No. [
 _____ 
]

	 	December 9, 2009
	$[
 _____ 
]

	 	PPN 89407# AF5

For Value Received, the undersigned, TRANSWESTERN PIPELINE COMPANY, LLC (herein
called the “Company"), a Delaware limited liability company, hereby promises to pay to [
 _____ 
], or
registered assigns, the principal sum of [
 _____ 
] DOLLARS (or so much thereof as shall not have been
prepaid) on December 9, 2020 with interest (computed on the basis of a 360-day year of twelve
30-day months) (a) on the unpaid balance hereof at the rate of 5.36% per annum from the date
hereof, payable semi-annually, on the 9th day of June and December in each year, commencing with
the 9th day of June next succeeding the date hereof, until the principal hereof shall have become
due and payable, and (b) to the extent permitted by law, at a rate per annum from time to time
equal to the greater of (i) 7.36% or (ii) 2% over the rate of interest publicly announced by Bank
of America, N.A. from time to time in New York, New York as its “base” or “prime” rate, on any
overdue payment of interest and, during the continuance of an Event of Default, on the unpaid
balance hereof and on any overdue payment of any Make-Whole Amount, payable semi-annually as
aforesaid (or, at the option of the registered holder hereof, on demand).

Subject to the home office payment obligation contained in Section 14.2 of the Note Purchase
Agreement referred to below, payments of principal of, interest on and any Make-Whole Amount with
respect to this Note are to be made in lawful money of the United States of America at such place
as the Company shall have designated by written notice to the holder of this Note as provided in
the Note Purchase Agreement referred to below.

This Note is one of a series 5.36% Senior Unsecured Series A Notes due December 9, 2020
(herein called the “Notes") issued pursuant to the Note Purchase Agreement, dated as of December 9,
2009 (as from time to time amended, supplemented or modified, the “Note Purchase Agreement"),
between the Company and the respective Purchasers named therein and is entitled to the benefits
thereof. Each holder of this Note will be deemed, by its acceptance hereof, to have agreed to the
confidentiality provisions set forth in Section 20 of the Note Purchase Agreement. Unless otherwise indicated,
capitalized terms used in this Note shall have the respective meanings ascribed to such terms in
the Note Purchase Agreement.

 

 

 

This Note is a registered Note and, as provided in the Note Purchase Agreement, upon surrender
of this Note for registration of transfer, duly endorsed, or accompanied by a written instrument of
transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized
in writing, a new Note for a like principal amount will be issued to, and registered in the name
of, the transferee. Prior to due presentment for registration of transfer, the Company may treat
the person in whose name this Note is registered as the owner hereof for the purpose of receiving
payment and for all other purposes, and the Company will not be affected by any notice to the
contrary.

This Note is subject to optional prepayment and offers of prepayment, in whole or from time to
time in part, at the times and on the terms specified in the Note Purchase Agreement, but not
otherwise.

If an Event of Default occurs and is continuing, the principal of this Note may be declared or
otherwise become due and payable in the manner, at the price (including any applicable Make-Whole
Amount) and with the effect provided in the Note Purchase Agreement.

This Note shall be construed and enforced in accordance with, and the rights of the Company
and holder hereof shall be governed by, and construed in accordance with, the law of the State of
New York.

	 	 	 	 	 
	 	TRANSWESTERN PIPELINE COMPANY, LLC

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:Exhibit 10.3

Exhibit 10.3

EXHIBIT 1(b)

This Note has not been registered pursuant to the Securities Act of 1933, as amended (the
“Securities Act"), or pursuant to the securities laws of any state. Accordingly, this Note may not
be offered, sold or otherwise transferred (1) except in accordance with an applicable exemption
from the registration requirements of the Securities Act and any applicable state securities laws
or (2) unless this Note is registered under the Securities Act and any applicable state securities
laws.

TRANSWESTERN PIPELINE COMPANY, LLC

5.66% Senior Unsecured Series B Note due December 9, 2024

	 	 	 
	No. [
 _____ 
]

	 	December 9, 2009
	$[
 _____ 
]

	 	PPN 89407# AG3

For Value Received, the undersigned, TRANSWESTERN PIPELINE COMPANY, LLC (herein
called the “Company"), a Delaware limited liability company, hereby promises to pay to [
 _____ 
], or
registered assigns, the principal sum of [
 _____ 
] DOLLARS (or so much thereof as shall not have been
prepaid) on December 9, 2024 with interest (computed on the basis of a 360-day year of twelve
30-day months) (a) on the unpaid balance hereof at the rate of 5.66% per annum from the date
hereof, payable semi-annually, on the 9th day of June and December in each year, commencing with
the 9th day of June next succeeding the date hereof, until the principal hereof shall have become
due and payable, and (b) to the extent permitted by law, at a rate per annum from time to time
equal to the greater of (i) 7.66% or (ii) 2% over the rate of interest publicly announced by Bank
of America, N.A. from time to time in New York, New York as its “base” or “prime” rate, on any
overdue payment of interest and, during the continuance of an Event of Default, on the unpaid
balance hereof and on any overdue payment of any Make-Whole Amount, payable semi-annually as
aforesaid (or, at the option of the registered holder hereof, on demand).

Subject to the home office payment obligation contained in Section 14.2 of the Note Purchase
Agreement referred to below, payments of principal of, interest on and any Make-Whole Amount with
respect to this Note are to be made in lawful money of the United States of America at such place
as the Company shall have designated by written notice to the holder of this Note as provided in
the Note Purchase Agreement referred to below.

This Note is one of a series 5.66% Senior Unsecured Series B Notes due December 9, 2024
(herein called the “Notes") issued pursuant to the Note Purchase Agreement, dated as of December 9,
2009 (as from time to time amended, supplemented or modified, the “Note Purchase Agreement"),
between the Company and the respective Purchasers named therein and is entitled to the benefits
thereof. Each holder of this Note will be deemed, by its acceptance hereof, to have agreed to the
confidentiality provisions set forth in Section 20 of the Note Purchase Agreement. Unless otherwise indicated,
capitalized terms used in this Note shall have the respective meanings ascribed to such terms in
the Note Purchase Agreement.

 

 

 

This Note is a registered Note and, as provided in the Note Purchase Agreement, upon surrender
of this Note for registration of transfer, duly endorsed, or accompanied by a written instrument of
transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized
in writing, a new Note for a like principal amount will be issued to, and registered in the name
of, the transferee. Prior to due presentment for registration of transfer, the Company may treat
the person in whose name this Note is registered as the owner hereof for the purpose of receiving
payment and for all other purposes, and the Company will not be affected by any notice to the
contrary.

This Note is subject to optional prepayment and offers of prepayment, in whole or from time to
time in part, at the times and on the terms specified in the Note Purchase Agreement, but not
otherwise.

If an Event of Default occurs and is continuing, the principal of this Note may be declared or
otherwise become due and payable in the manner, at the price (including any applicable Make-Whole
Amount) and with the effect provided in the Note Purchase Agreement.

This Note shall be construed and enforced in accordance with, and the rights of the Company
and holder hereof shall be governed by, and construed in accordance with, the law of the State of
New York.

	 	 	 	 	 
	 	TRANSWESTERN PIPELINE COMPANY, LLC

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:Exhibit 10.1

Exhibit 10.1

FORM OF EXECUTIVE SEVERANCE AND NONCOMPETITION AGREEMENT

THIS SEVERANCE AND NONCOMPETITION AGREEMENT (the “Agreement”), dated as of
                                        , is by and between HealthSpring, Inc., a Delaware corporation (collectively
with its Subsidiaries, the “Company”), and
                                         (“Employee”).

WHEREAS, the Company and Employee have each agreed to execute this Agreement to provide for
the rights and obligations set forth herein.

NOW THEREFORE, in consideration of the mutual covenants contained herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows:

1. Definitions. Words or phrases that are initially capitalized or within quotation
marks shall have the meanings provided in this Section 1 and as provided elsewhere in this
Agreement. For purposes of this Agreement, the following definitions apply:

“Accrued Obligations” shall mean, as of the date of termination, the sum of (A)
Employee’s then-current base salary (disregarding any reduction constituting Good Reason) through
the date of termination to the extent not theretofore paid by the Company and (B) any vacation pay,
sick pay, and expense reimbursements earned and accrued by Employee as of the date of termination
to the extent not theretofore paid by the Company.

“Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

“Board” shall mean the Board of Directors of the Company.

“Cause” shall mean, with respect to Employee, one or more of the following: (i) the
conviction of a felony or a crime involving moral turpitude; (ii) the commission of any act or
omission involving material dishonesty or fraud with respect to the Company or any of its
Subsidiaries; (iii) reporting to work under the influence of illegal drugs or the use of illegal
drugs (whether or not at the workplace); (iv) repeated conduct causing the Company or any of its
Subsidiaries substantial public disgrace or disrepute or substantial economic harm; (v) the
continued and repeated failure to perform substantially the duties of his or her employment after
30 days’ notice from the Company, such notice setting forth in reasonable detail the nature of such
failure, and in the event Employee fails to cure such failure within 30 days of notice from the
Company, if such failure is capable of being cured; (vi) breach of fiduciary duty or engaging in
gross negligence or willful misconduct with respect to the Company or any of its Subsidiaries; or
(vii) any other material breach of this Agreement which is not cured within 30 days after written
notice thereof to Employee.

“Change of Control” shall mean any of the following events:

(i) any Person, other than the Company or any of its Subsidiaries or any employee benefit plan
of the Company or any of its Subsidiaries, becomes the beneficial owner of the Company’s securities
having 35% or more of the combined voting power of the then outstanding securities of the Company
that may be cast for the election of directors of the Company (other than as a result of an
issuance of securities initiated by the Company in the ordinary course of business);

 

 

 

(ii) as the result of, or in connection with, any cash tender or exchange offer, merger or
other business combination or contested election, or any combination of the foregoing transactions,
less than a
majority of the combined voting power of the then outstanding securities of the Company or any
successor company or entity entitled to vote generally in the election of the directors of the
Company or such other corporation or entity after such transaction are held in the aggregate by the
holders of the Company’s securities entitled to vote generally in the election of directors of the
Company immediately prior to such transaction;

(iii) during any period of two consecutive years, individuals who at the beginning of any such
period constitute the Board cease for any reason to constitute at least a majority thereof, unless
the election, or the nomination for election by the Company’s stockholders, of each director of the
Company first elected during such period was approved by a vote of at least two-thirds (2/3rds) of
the directors of the Company then still in office who were (i) directors of the Company at the
beginning of any such period, and (ii) not initially (a) appointed or elected to office as result
of either an actual or threatened election and/or proxy contest by or on behalf of a Person other
than the Board, or (b) designated by a Person who has entered into an agreement with the Company to
effect a transaction described in (i) or (ii) above or (iv) or (v) below;

(iv) a complete liquidation or dissolution of the Company; or

(v) the sale or other disposition of all or substantially all of the assets of the Company to
any Person (other than a transfer to a Subsidiary).

“Change of Control Termination” shall mean a Qualifying Termination that takes place
on the day of, or within 24 months after, the occurrence of a Change of Control.

“Code” shall mean the United States Internal Revenue Code of 1986, as amended from
time to time.

“Confidential Information” shall mean any and all information of the Company and its
Subsidiaries that is not generally known by others with whom they compete or do business, or with
whom they plan to compete or do business, and any and all information, which, if disclosed by the
Company or any of its Subsidiaries, would assist in competition against any of them. Confidential
Information includes without limitation information relating to the historic and projected
financial performance and strategic plans of the Company and its Subsidiaries. Confidential
Information also includes any and all information that the Company or any of its Subsidiaries has
received from others with any understanding that it would not be disclosed.

“Good Reason” shall mean if Employee resigns from his or her employment with the
Company and its Subsidiaries in connection with one or more of the following events: (i) a
reduction of 10% or more of Employee’s base salary; (ii) a reduction of 10% or more of Employee’s
annual target bonus opportunity; (iii) any material reduction to the nature or scope of Employee’s
responsibilities, which is not cured within 30 days after written notice thereof by Employee to the
Company; or (iv) a requirement by the Company, without Employee’s consent, to relocate Employee to
a location that is greater than 50 miles from the location of the office in which Employee
primarily performs his or her duties of employment at the time of such relocation; provided that
written notice of Employee’s resignation for Good Reason must be delivered to the Company within 45
days after the occurrence of any such event in order for Employee’s resignation with Good Reason to
be effective hereunder.

“Payment” means any payment or distribution in the nature of compensation (within the
meaning of Section 280G(b)(2)(A) of the Code) to or for the benefit of Employee, whether paid or
payable pursuant to this Agreement or otherwise pursuant to any plan, agreement or understanding
between Employee and the Company, which, within the meaning of Section 280G(b)(2)(A)(i) of the
Code, is contingent on a change in the ownership or effective control of the Company, or in the
ownership of a substantial portion of the assets of the Company.

 

2

 

“Person” means an individual, a corporation, an association, a partnership, an estate,
a trust or other entity or organization (including a “group” as defined in Section 13(d)(3) or
14(d)(2) of the Act).

“Qualifying Termination” shall mean a termination of Employee’s employment (i) by the
Company and its Subsidiaries without Cause (and other than due to Employee’s death or disability)
or (ii) by Employee for Good Reason.

“Subsidiary” shall mean any corporation, partnership, limited liability company, or
other business entity of which more than 50% of the total voting power of shares of stock or other
ownership interests is owned by the Company.

2. Change of Control Severance Benefits. In the event of a Change of Control
Termination, in addition to Employee’s Accrued Obligations, Employee shall be entitled to receive
severance pay equal to two times the sum of (A) Employee’s base salary in effect immediately prior
to such termination (disregarding any reduction constituting Good Reason) and (B) Employee’s target
annual bonus for the year in which such termination occurs (disregarding any reduction constituting
Good Reason), which, subject to Section 4 hereof, shall be paid to Employee by the Company
in a lump sum no later than 30 days following the date of the Change of Control Termination,
provided, however, that if the Change of Control Termination occurs within the last 45 days of a
calendar year, in no event shall any payment be made pursuant to this Section 2 prior to
January 1 of the next succeeding calendar year. For a period of two years following the date of
the Change of Control Termination (the “Change of Control Severance Period”), the Company
shall continue to provide, at the Company’s expense, medical and dental insurance benefits to
Employee (and all family members and other dependents of Employee who were enrolled in such
programs as of the date of the Change of Control Termination) on substantially the same terms and
conditions existing immediately prior to the Change of Control Termination.

3. Severance Benefits. If Employee’s employment with the Company and its Subsidiaries
is terminated due to a Qualifying Termination that is not a Change in Control Termination, in
addition to Employee’s Accrued Obligations, Employee shall be entitled to receive severance pay
equal to [two times][1.5 times] Employee’s base salary in effect immediately prior to such
termination (disregarding any reduction constituting Good Reason), which, subject to Section
4 hereof, shall be paid by the Company to Employee in regular installments, in accordance with
the Company’s normal payroll policies then in effect, for a period of [24][18] months following the
date of the Qualifying Termination. These payments will commence with the payroll period following
the date on which the Qualifying Termination occurs (or, if later, the expiration of any revocation
period applicable to the release described in Section 4 hereof, provided that if a
Qualifying Termination occurs within the last 30 days of a calendar year, in no event shall
payments commence prior to January 1 of the next succeeding calendar year) (such [24][18]-month
period, the “Severance Period”). For a period of 18 months following the date of the
Qualifying Termination, the Company shall continue to provide, at the Company’s expense, medical
and dental insurance benefits to Employee (and all family members and other dependents of Employee
who were enrolled in such programs as of the date of the Qualifying Termination) on substantially
the same terms and conditions existing immediately prior to the Qualifying Termination.

4. Conditions. Any payments or benefits made or provided pursuant to this Agreement
shall be available if and only if Employee has executed and delivered to the Company the General
Release substantially in form and substance as set forth in Exhibit A attached hereto, the
General Release has become effective, Employee has not revoked or breached the provisions of the
General Release or breached the provisions of Section 5 or Section 6 hereof, all
applicable revocation periods with respect to such release have expired, and Employee does not
apply for unemployment compensation chargeable to the Company or any Subsidiary. In no event shall
cash severance payments received pursuant to Section 2 or Section 3 hereof be
reduced as a result of the receipt by Employee of compensation or benefits from a
Person other than the Company during the Severance Period or Change of Control Severance
Period, as applicable. All medical and dental insurance benefits made or provided pursuant to this
Agreement shall be reduced by the amount of any comparable benefits Employee receives with respect
to any other employment during the Severance Period or Change of Control Severance Period, as
applicable; provided that Employee shall have no duty or obligation to seek other employment during
any Severance Period or Change of Control Severance Period or otherwise mitigate damages hereunder.
Upon request from time to time, Employee shall furnish the Company with a true and complete
certificate specifying any such benefits received by Employee from any Person other than the
Company during the Severance Period or Change of Control Severance Period, as applicable.

 

3

 

5. Noncompete/Nonsolicitation.

5.1 In further consideration of the benefits to Employee hereunder and as a condition
of his or her continued employment with the Company and its Subsidiaries, Employee
acknowledges that during the course of his or her employment with the Company and its
Subsidiaries, Employee has and will become familiar with the Company’s and its Subsidiaries’
trade secrets and with other Confidential Information concerning the Company and its
Subsidiaries and that Employee’s services have been and shall continue to be of special,
unique, and extraordinary value to the Company and its Subsidiaries. Employee agrees that,
during his or her employment with the Company and its Subsidiaries and for twelve months
thereafter (the “Noncompete Period”), Employee shall not directly or indirectly own
any interest in, manage, control, participate in, consult with, render services for, be
employed in an executive, managerial or administrative capacity by, or in any manner engage
in any business within the United States that is engaging in the businesses of the Company
or its Subsidiaries, as such businesses exist at any time during his or her employment with
the Company and its Subsidiaries or, as of the date of termination of such employment, are
contemplated to exist during the twelve-month period following the date of termination of
employment (the “Restricted Business”). Nothing herein shall prohibit Employee from
(i) being a passive owner of not more than 2% of the outstanding stock of any class of a
corporation that is publicly traded, so long as Employee has no active participation in the
business of such corporation; or (ii) becoming employed, engaged, associated or otherwise
participating with a separately managed division or subsidiary of a competitive business
that does not engage in the Restricted Business (provided that Employee’s services are
provided only to such division or subsidiary); or (iii) accepting employment with any
federal or state government or governmental subdivision or agency.

5.2 During the Noncompete Period, Employee shall not directly or indirectly through
another Person (i) induce or attempt to induce any employee of the Company or any Subsidiary
to leave the employ of the Company or such Subsidiary, or in any way interfere with the
relationship between the Company or any Subsidiary and any employee thereof; (ii) hire any
Person who was an employee of the Company or any Subsidiary at any time during the
twelve-month period immediately prior to the termination of his employment with the Company;
or (iii) induce or attempt to induce any member, provider, payor or other business relation
of the Company or any Subsidiary to cease or materially reduce doing business with the
Company or such Subsidiary, or in any way interfere with the relationship between any such
customer, supplier, licensee or business relation and the Company or any Subsidiary
(including, without limitation, making any negative or disparaging statements or
communications regarding the Company or its Subsidiaries). Notwithstanding the foregoing,
nothing in this Agreement shall prohibit Employee from employing an individual (i) with the
consent of the Company or (ii) who responds to general solicitations in publications or on
websites, or through the use of search firms, so long as such general solicitations or
search firm activities are not targeted specifically
at an employee of the Company or any of its Subsidiaries. In addition, nothing in this
Agreement will prohibit the making of any truthful statements made by any Person in response
to a lawful subpoena or legal proceeding or to enforce such Person’s rights under this
Agreement, or any other agreement between Employee, the Company, and its Subsidiaries.

 

4

 

6. Confidentiality; Trade Secrets.

6.1 Employee acknowledges that the Company and its Subsidiaries continually develop
Confidential Information, that Employee may develop Confidential Information for the Company
or its Subsidiaries, and that Employee may learn of Confidential Information during the
course of his or her employment. Employee agrees that all Confidential Information that
Employee creates or to which Employee has access as a result of Employee’s employment,
whether before or after the date of this Agreement, is and shall remain the sole and
exclusive property of the Company and that Employee will comply with the policies and
procedures of the Company and its Subsidiaries for protecting Confidential Information.
Employee further agrees that, except as required for the proper performance of Employee’s
duties for the Company or as required by applicable law (and then only to the extent
required), Employee will not, directly or indirectly, use for Employee’s own benefit or
gain, or assist others in the application of, or disclose any Confidential Information.
Employee understands and agrees that these restrictions will continue to apply after
Employee’s employment terminates, regardless of the reason for termination and regardless
whether Employee is receiving or is entitled to receive any payments or other benefits under
this Agreement.

6.2 Employee acknowledges that all discoveries, concepts, ideas, inventions,
innovations, improvements, developments, methods, designs, analyses, drawings, reports,
patent applications, copyrightable work and mask work (whether or not including any
Confidential Information) and all registrations or applications related thereto, all other
proprietary information and all similar or related information (whether or not patentable)
that relate to the Company’s or any of its Subsidiaries’ actual or anticipated business,
research and development or existing or future products or services and that are conceived,
developed or made by Employee (whether alone or jointly with others) while employed by the
Company and its Subsidiaries, whether before or after the date of this Agreement (“Work
Product”), belong to the Company or such Subsidiary. Employee shall promptly disclose
all patentable inventions and other material Work Product to the Board and, at the Company’s
expense, perform all actions reasonably requested by the Board (whether during or after his
or her employment with the Company and its Subsidiaries) to establish and confirm such
ownership (including, without limitation, assignments, consents, powers of attorney and
other instruments). Employee acknowledges that all Work Product shall be deemed to
constitute “works made for hire” under the U.S. Copyright Act of 1976, as amended. In
accordance with Title 19, Section 805 of the Delaware Code, Employee is hereby advised that
this Section 6.2 regarding the Company’s and its Subsidiaries’ ownership of Work
Product does not apply to any invention for which no equipment, supplies, facilities or
trade secret information of the Company or any Subsidiary was used and which was developed
entirely on Employee’s own time, unless (i) the invention relates to the business of the
Company or any Subsidiary or to the Company’s or any Subsidiaries’ actual or demonstrably
anticipated research or development, or (ii) the invention results from any work performed
by Employee for the Company or any Subsidiary.

 

5

 

7. Enforceability and Remedies.

7.1 Employee agrees that the restrictions on, and other provisions relating to,
Employee’s activities contained in this Agreement are fully reasonable and necessary to
protect the goodwill, Confidential Information, and other legitimate interests of the
Company. Employee
also acknowledges and agrees that, were Employee to breach the provisions of this Agreement,
the harm to the Company would be irreparable. Employee therefore agrees that in the event
of such a breach or threatened breach the Company shall, in addition to any other remedies
available to it, have the right to obtain preliminary and permanent injunctive relief
against any such breach without having to post bond. Employee further agrees that, in
addition to any other relief awarded to the Company as a result of Employee’s breach of any
of the provisions of this Agreement, the Company shall be entitled to recover all payments
made to Employee or on Employee’s behalf hereunder.

7.2 Employee hereby agrees that in the event any provision of this Agreement shall be
determined by any court of competent jurisdiction to be unenforceable by reason of its being
extended over too long a time, too large a geographic area, or too great a range of
activities, such provision shall be deemed to be modified to permit its enforcement to the
maximum extent permitted by law.

8. Assignment. Neither the Company nor Employee may make any assignment of this
Agreement or any interest herein, by operation of law or otherwise, without the prior written
consent of the other; provided, however, that the Company may assign its rights and obligations
under this Agreement without Employee’s consent in the event that the Company shall hereafter
effect a Change of Control. This Agreement shall inure to the benefit of and be binding upon the
Company, its successors (including without limitation any transferee of all or substantially all of
its assets), and permitted assigns and upon Employee, Employee’s executors, administrators, heirs,
and permitted assigns. In the event of any Change of Control, references to the Company in this
Agreement shall, unless the context suggests otherwise, be deemed to include the entity resulting
from such Change of Control of the Company. The Company shall require any successor (whether
direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of
the business or assets of the Company to expressly assume this Agreement and all obligations of the
Company hereunder in the same manner and to the same extent that the Company would be so obligated
if no such succession had taken place.

9. Notices. Any and all notices, requests, demands, acceptances, appointments and
other communications provided for by this Agreement shall be in writing (including electronic mail
or similar electronic transmission) and shall be effective when actually delivered in person or, if
mailed, five days after having been deposited in the United States mail, postage prepaid,
registered or certified and addressed to Employee at Employee’s last known address on the books of
the Company or, in the case of the Company, addressed to its principal place of business, attention
General Counsel, or to such other address as either party may specify by notice to the other.

10. Withholding. All compensation paid or provided to Employee under this Agreement
shall be subject to any applicable income, payroll or other tax withholding requirements.

 

6

 

11. Section 409A. It is intended that (1) each installment of the payments provided
under this Agreement is a separate “payment” for purposes of Section 409A of the Code, and (2) that
the payments satisfy, to the greatest extent possible, the exemptions from the application of Code
Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(9)(iii), and
1.409A-1(b)(9)(v). Notwithstanding anything to the contrary in this Agreement, if the Company
determines (i) that on the date Employee’s employment with the Company terminates or at such other
time that the Company determines to be relevant, Employee is a “specified employee” (as such term
is defined under Treasury Regulation 1.409A-1(i)(1)) of the Company and (ii) that any payments to
be provided to Employee pursuant to this Agreement are or may become subject to the additional tax
under Code Section 409A(a)(1)(B) or any other taxes or penalties imposed under Code Section 409A
(“Section 409A Taxes”) if provided at the time otherwise required under this Agreement, then such
payments shall be delayed until the date that is six months after the date of Employee’s
“separation from service” (as such term is
defined under Treasury Regulation 1.409A-1(h)) with the Company, or such shorter period that,
as determined by the Company, is sufficient to avoid the imposition of Section 409A Taxes. For the
avoidance of doubt, it is anticipated that payments qualifying for the exemption from application
of Section 409A pursuant to Treasury Regulation 1.409A-1(b)(9)(iii) will be made during this six
month period, if applicable. Any payments delayed pursuant to this Section 11 shall be
made in a lump sum on the first day of the seventh month following Employee’s “separation from
service” (as such term is defined under Treasury Regulation 1.409A-1(h)), or such earlier date
that, as determined by the Company, is sufficient to avoid the imposition of any Section 490A
Taxes.

12. Section 280G. Notwithstanding anything in this Agreement to the contrary, in the
event that it shall be determined that any Payment would constitute an “excess parachute payment”
within the meaning of Section 280G(b) of the Code, the Payment(s) shall be reduced by an amount
necessary to prevent any portion of the Payment(s) from being a “parachute payment” as defined in
Section 280G(b)(2) of the Code. The value of Payment(s) for purposes of this Section 12
shall be established by an independent certified public accounting firm designated by the Company
and by applying principles, assumptions, and procedures consistent with Section 280G of the Code.

13. Other Arrangements. If any provision of this Agreement conflicts with any other
agreement, policy, plan, practice, or other Company document, then the provisions of this Agreement
shall control. This Agreement shall supersede and replace any prior employment, change of control
or severance agreement between Employee and the Company (excluding any equity plan or equity award
agreement) and may be amended only by a writing signed by an officer of the Company and Employee.

14. Miscellaneous. The headings and captions in this Agreement are for convenience
only and in no way define or describe the scope or content of any provision of this Agreement.
Nothing herein shall be deemed to create an employment contract, and Employee acknowledges that his
or her employment by the Company is terminable at will by either party with or without cause and
with or without notice. This Agreement may not be modified, waived, or discharged unless such
waiver, modification, or discharge is agreed to in a writing signed by Employee and a duly
authorized officer of the Company. The validity, interpretation, construction, and performance of
this Agreement shall be governed by the laws of the State of Delaware, without giving effect to
choice of law or conflict of law rules or provisions thereof. The parties agree that, in the event
it becomes necessary to seek judicial remedies for the breach or threatened breach of this
Agreement, the prevailing party will be entitled, in addition to all other remedies, to recover
from the non-prevailing party reasonable attorneys’ fees and costs upon the entry of a final
nonappealable judgment. Each party shall perform such further acts and execute and deliver such
further documents as may be reasonably necessary to carry out the provisions of this Agreement. By
accepting this agreement, Employee hereby agrees and acknowledges that the Company makes no
representations with respect to the application of Code Section 409A to any tax, economic, or legal
consequences of any payments payable to Employee hereunder (including, without limitation, payments
pursuant to Section 2 and Section 3 above) and, by the acceptance of this
Agreement, Employee agrees to accept the potential application of Code Section 409A to the tax and
legal consequences of payments payable to Employee hereunder (including, without limitation,
payments pursuant to Section 2 and Section 3 above). The parties agree to
cooperate in good faith to amend such documents and to take such actions as may be necessary or
appropriate to comply with Code Section 409A.

This Agreement may be executed in two or more counterparts, each of which shall be an original
and all of which together constitute one and the same instrument. If any term or other provision
of this Agreement is invalid, illegal, or incapable of being enforced by any rule of law, or public
policy, all other conditions and provisions of this Agreement shall nevertheless remain in full
force and effect so long as the economic or legal substance of the transactions contemplated hereby
is not affected in any manner adverse to any party. Upon such determination that any term or other
provision is invalid, illegal, or
incapable of being enforced, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties as closely as possible in an
acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest
extent possible.

 

7

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the
date first written above.

	 	 	 	 	 
	 	 	HEALTHSPRING, INC.
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 
	 

	 	 	Its:	 
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	EMPLOYEE
	 
	 	 	 	 
	 	 	 

 

8

 

Exhibit A

GENERAL RELEASE

I,                     , in consideration of and subject to the performance by HealthSpring, Inc., a
Delaware corporation (together with each of its Subsidiaries, the “Company”), of its
obligations under the Severance and Noncompetition Agreement, dated as of the date as of
                     (the “Agreement”), do hereby release and forever discharge as of the date
hereof the Company and its affiliates and all present and former directors, officers, agents,
representatives, employees, successors and assigns of the Company and its affiliates and the
Company’s direct or indirect owners (collectively, the “Released Parties”) to the extent
provided below.

	1.	 	I understand that any payments or benefits paid or granted to me under Section 1 of the
Agreement represent, in part, consideration for signing this General Release and are not
salary, wages or benefits to which I was already entitled. I understand and agree that I will
not receive the payments and benefits specified in Section 2 or Section 3 of the Agreement
unless I execute this General Release and do not revoke this General Release within the time
period permitted hereafter or breach this General Release. Such payments and benefits will
not be considered compensation for purposes of any employee benefit plan, program, policy or
arrangement maintained or hereafter established by the Company or its affiliates. I also
acknowledge and represent that I have received all payments and benefits that I am entitled to
receive (as of the date hereof) by virtue of any employment by the Company.

	2.	 	Except as provided in paragraph 4 below, I knowingly and voluntarily (for myself, my heirs,
executors, administrators and assigns) release and forever discharge the Company and the other
Released Parties from any and all claims, suits, controversies, actions, causes of action,
cross-claims, counter-claims, demands, debts, compensatory damages, liquidated damages,
punitive or exemplary damages, other damages, claims for costs and attorneys’ fees, or
liabilities of any nature whatsoever in law and in equity, both past and present (through the
date this General Release becomes effective and enforceable) and whether known or unknown,
suspected, or claimed against the Company or any of the Released Parties which I, my spouse,
or any of my heirs, executors, administrators or assigns, may have, which arise out of or are
connected with my employment with, or my separation or termination from, the Company
(including, but not limited to, any allegation, claim or violation, arising under: Title VII
of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; the Age
Discrimination in Employment Act of 1967, as amended (including the Older Workers Benefit
Protection Act); the Equal Pay Act of 1963, as amended; the Americans with Disabilities Act of
1990; the Family and Medical Leave Act of 1993; the Worker Adjustment Retraining and
Notification Act; the Employee Retirement Income Security Act of 1974; any applicable
Executive Order Programs; the Fair Labor Standards Act; or their state or local counterparts;
or under any other federal, state or local civil or human rights law, or under any other
local, state, or federal law, regulation or ordinance; or under any public
policy, contract or tort, or under common law; or arising under any policies, practices or
procedures of the Company; or any claim for wrongful discharge, breach of contract,
infliction of emotional distress, defamation; or any claim for costs, fees, or other
expenses, including attorneys’ fees incurred in these matters) (all of the foregoing
collectively referred to herein as the “Claims”).

	3.	 	I represent that I have made no assignment or transfer of any right, claim, demand, cause of
action, or other matter covered by paragraph 2 above.

 

A-1

 

	4.	 	I agree that this General Release does not waive or release any rights or claims that I
may have under the Age Discrimination in Employment Act of 1967 which arise after the date I
execute this General Release. I acknowledge and agree that my separation from employment
with the Company in compliance with the terms of the Agreement shall not serve as the
basis for any claim or action (including, without limitation, any claim under the Age
Discrimination in Employment Act of 1967).

	5.	 	In signing this General Release, I acknowledge and intend that it shall be effective as a bar
to each and every one of the Claims hereinabove mentioned or implied. I expressly consent that
this General Release shall be given full force and effect according to each and all of its
express terms and provisions, including those relating to unknown and unsuspected Claims
(notwithstanding any state statute that expressly limits the effectiveness of a general
release of unknown, unsuspected and unanticipated Claims), if any, as well as those relating
to any other Claims hereinabove mentioned or implied. I acknowledge and agree that this waiver
is an essential and material term of this General Release and that without such waiver the
Company would not have agreed to the terms of the Agreement. I further agree that in the
event I should bring a Claim seeking damages against the Company, or in the event I should
seek to recover against the Company in any Claim brought by a governmental agency on my
behalf, this General Release shall serve as a complete defense to such Claims. I further agree
that I am not aware of any pending charge or complaint of the type described in paragraph 2 as
of the execution of this General Release.

	6.	 	I agree that neither this General Release, nor the furnishing of the consideration for this
General Release, shall be deemed or construed at any time to be an admission by the Company,
any Released Party or myself of any improper or unlawful conduct.

	7.	 	I agree that I will forfeit all amounts payable by the Company pursuant to the Agreement if I
challenge the validity of this General Release. I also agree that if I violate this General
Release by suing the Company or the other Released Parties, I will pay all costs and expenses
of defending against the suit incurred by the Released Parties, including reasonable
attorneys’ fees, and return all payments received by me pursuant to the Agreement.

	8.	 	I agree that this General Release is confidential and agree not to disclose any information
regarding the terms of this General Release, except to my immediate family and any tax, legal
or other counsel I have consulted regarding the meaning or effect hereof or as required by
law, and I will instruct each of the foregoing not to disclose the same to anyone.
Notwithstanding anything herein to the contrary, each of the parties (and each affiliate and
person acting on behalf of any such party) agree that each party (and each employee,
representative, and other agent of such party) may disclose to any and all persons, without
limitation of any kind, the tax treatment and tax structure of this transaction contemplated
in the Agreement and all materials of any kind (including opinions or other tax analyses) that
are provided to such party or such person relating to such tax treatment and tax structure,
except to the extent necessary to comply with any applicable federal or state securities laws.
This authorization is not intended to permit disclosure
of any other information including (without limitation) (i) any portion of any materials to
the extent not related to the tax treatment or tax structure of this transaction, (ii) the
identities of participants or potential participants in the Agreement, (iii) any financial
information (except to the extent such information is related to the tax treatment or tax
structure of this transaction), or (iv) any other term or detail not relevant to the tax
treatment or the tax structure of this transaction.

 

A-2

 

	9.	 	Any non-disclosure provision in this General Release does not prohibit or restrict me (or
my attorney) from responding to any inquiry about this General Release or its underlying
facts and circumstances by the Securities and Exchange Commission (SEC), the Financial
Industry Regulatory Authority (FINRA), any other self-regulatory organization or
governmental entity.

	10.	 	I agree to reasonably cooperate with the Company in any internal investigation, any
administrative, regulatory, or judicial proceeding or any dispute with a third party.

	11.	 	I agree not to disparage the Company, its past and present investors, officers, directors or
employees or its affiliates and to keep all confidential and proprietary information about the
past or present business affairs of the Company and its affiliates confidential in accordance
with the terms of the Agreement unless a prior written release from the Company is obtained.
I further agree that as of the date hereof, I have returned to the Company any and all
property, tangible or intangible, relating to its business, which I possessed or had control
over at any time (including, but not limited to, Company-provided credit cards, building or
office access cards, keys, computer equipment, manuals, files, documents, records, software,
customer data base and other data) and that I shall not retain any copies, compilations,
extracts, excerpts, summaries or other notes of any such manuals, files, documents, records,
software, customer data base or other data.

	12.	 	Notwithstanding anything in this General Release to the contrary, this General Release shall
not relinquish, diminish, or in any way affect (i) any rights or claims arising out of any
breach by the Company or by any Released Party of the Agreement after the date hereof, (ii)
any rights or obligations under applicable law which cannot be waived or released pursuant to
an agreement, (iii) any rights to payments or benefits under Section 2 or Section 3 of the
Agreement, (iv) my rights of indemnification and directors and officers insurance coverage to
which I may be entitled solely with regards to my service as an officer or director of the
Company; (v) my rights with regard to accrued benefits under any employee benefit plan, policy
or arrangement maintained by the Company or under COBRA; and (vi) my rights as a stockholder
or other equityholder of the Company and/or its affiliates.

	13.	 	Whenever possible, each provision of this General Release shall be interpreted in, such
manner as to be effective and valid under applicable law, but if any provision of this General
Release is held to be invalid, illegal or unenforceable in any respect under any applicable
law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not
affect any other provision or any other jurisdiction, but this General Release shall be
reformed, construed and enforced in such jurisdiction as if such invalid, illegal or
unenforceable provision had never been contained herein.

BY SIGNING THIS GENERAL RELEASE, I REPRESENT AND AGREE THAT:

	(a)	 	I HAVE READ IT CAREFULLY;

	(b)	 	I UNDERSTAND ALL OF ITS TERMS AND KNOW THAT I AM GIVING UP IMPORTANT RIGHTS, INCLUDING BUT
NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED,
TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED; THE EQUAL PAY ACT OF 1963, THE
AMERICANS WITH DISABILITIES ACT OF 1990; AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF
1974, AS AMENDED;

	 
	(c)	 	I VOLUNTARILY CONSENT TO EVERYTHING IN IT;

	 
	(d)	 	I HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT AND I HAVE DONE SO OR,
AFTER CAREFUL READING AND CONSIDERATION I HAVE CHOSEN NOT TO DO SO OF MY OWN VOLITION;

 

A-3

 

	(e)	 	I HAVE HAD AT LEAST 21 DAYS FROM THE DATE OF MY RECEIPT OF THIS RELEASE SUBSTANTIALLY IN
ITS FINAL FORM ON [_____,
 _____] TO CONSIDER IT AND THE CHANGES MADE SINCE THE
[_____,
 _____]

	 
	 	 	VERSION OF THIS RELEASE ARE NOT MATERIAL AND WILL NOT RESTART THE REQUIRED 21-DAY PERIOD;

	(f)	 	THE CHANGES TO THE AGREEMENT SINCE [_____,
 _____] EITHER ARE NOT MATERIAL OR
WERE MADE AT MY REQUEST.

	(g)	 	I UNDERSTAND THAT I HAVE SEVEN DAYS AFTER THE EXECUTION OF THIS RELEASE TO REVOKE IT AND THAT
THIS RELEASE SHALL NOT BECOME EFFECTIVE OR ENFORCEABLE UNTIL THE REVOCATION PERIOD HAS
EXPIRED;

	(h)	 	I HAVE SIGNED THIS GENERAL RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY
COUNSEL RETAINED TO ADVISE ME WITH RESPECT TO IT; AND

	(i)	 	I AGREE THAT THE PROVISIONS OF THIS GENERAL RELEASE MAY NOT BE AMENDED, WAIVED, CHANGED OR
MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE
COMPANY AND BY ME.

	 	 	 	 	 	 	 
	DATE:
	 	 	 	 	 	 
	 

	 	 

	 	 

	 	 
	ACCEPTED:	 	 	 	 
	 
	 	 	 	 	 	 
	HEALTHSPRING, INC.	 	 	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 

	 	 	 	 	 
	 	Title:
	 	 	 	 	 
	 

	 	 	 	 	 	 
	 
	Date:
	 	 	 	 	 	 
	 

	 	 	 	 	 

 

A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]